A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk

IF 6.7 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-09-23 DOI:10.1111/apt.18275
Karl Mårild, Jonas Söderling, Jordan Axelrad, Jonas Halfvarson, Anders Forss, SWIBREG Study Group, Karl Michaëlsson, Ola Olén, Jonas F. Ludvigsson
{"title":"A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk","authors":"Karl Mårild,&nbsp;Jonas Söderling,&nbsp;Jordan Axelrad,&nbsp;Jonas Halfvarson,&nbsp;Anders Forss,&nbsp;SWIBREG Study Group,&nbsp;Karl Michaëlsson,&nbsp;Ola Olén,&nbsp;Jonas F. Ludvigsson","doi":"10.1111/apt.18275","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To determine the fracture risk in IBD during periods with and without histological inflammation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990–2016 with longitudinal data on ileo-colorectal biopsies. Fractures were identified by inpatient and hospital-based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio-demographics, comorbidities, IBD duration, IBD-related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29–1.46) fractures per 100 years' follow-up versus 1.31 (95% CI 1.19–1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00–1.26; <i>p</i> = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91–1.36) and ulcerative colitis (1.18; 95% CI 1.02–1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid-naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07–1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87–1.92).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Histological inflammation in IBD predicted a small increase in short-term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"60 11-12","pages":"1549-1560"},"PeriodicalIF":6.7000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18275","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18275","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity.

Aims

To determine the fracture risk in IBD during periods with and without histological inflammation.

Methods

We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990–2016 with longitudinal data on ileo-colorectal biopsies. Fractures were identified by inpatient and hospital-based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio-demographics, comorbidities, IBD duration, IBD-related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.

Results

Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29–1.46) fractures per 100 years' follow-up versus 1.31 (95% CI 1.19–1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00–1.26; p = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91–1.36) and ulcerative colitis (1.18; 95% CI 1.02–1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid-naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07–1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87–1.92).

Conclusions

Histological inflammation in IBD predicted a small increase in short-term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项关于炎症性肠病、组织学活动和骨折风险的全国性队列研究。
背景:炎症性肠病(IBD)患者的骨折风险增加。目的:确定IBD患者在有组织学炎症和无组织学炎症期间的骨折风险:我们对 1990-2016 年间全国范围内 54,591 名被诊断为 IBD 患者的队列进行了研究,并获得了回肠直肠活检的纵向数据。骨折是通过住院病人和医院门诊诊断确定的。在对社会人口统计学、合并症、IBD 病程、IBD 相关手术和住院治疗进行调整后,我们得出了组织学炎症(与组织学缓解)记录后 12 个月内骨折的 Cox 回归估计危险比 (HRs)。我们对包括皮质类固醇在内的 IBD 药物治疗进行了敏感性分析调整:组织学炎症和缓解期患者活检时的平均年龄分别为 44.0 岁(SD = 18.3)和 45.5 岁(SD = 17.1)。组织学炎症患者每随访100年会发生1.37(95% CI 1.29-1.46)例骨折,而缓解期患者每随访100年会发生1.31(95% CI 1.19-1.44)例骨折(调整后[a]HR为1.12;95% CI为1.00-1.26;P = 0.04)。克罗恩病(1.11;95% CI 0.91-1.36)和溃疡性结肠炎(1.18;95% CI 1.02-1.36)组织学炎症的 HR 值相似。各年龄组的估计值一致。在考虑皮质类固醇后,任何骨折的总体超额风险仍然很小。在皮质类固醇无效的 IBD 患者中,组织学炎症与组织学缓解相比,骨折风险明显升高(aHR 1.41;95% CI 1.07-1.85)。组织学炎症后髋部骨折的aHR为1.29(95% CI 0.87-1.92):结论:IBD组织学炎症可预测短期骨折风险的小幅增加。减少疾病活动的措施可降低 IBD 患者的骨折风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Editorial: Dysfunctional Neutrophils in Cirrhosis With Acute Decompensation-Why It Matters. Authors' Reply. Editorial: Dysfunctional Neutrophils in Cirrhosis With Acute Decompensation: Why It Matters. Editorial: Decoding Gut Failure in Cirrhosis-Villin-1 and the Emergence of a Seventh Organ Failure. Authors' Reply. Editorial: Decoding Gut Failure in Cirrhosis: Villin-1 and the Emergence of a Seventh Organ Failure. Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1